K2 Principal Fund, L.P. Atea Pharmaceuticals, Inc. Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
52.4MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$29.6 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$21.5 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$17.6 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.85MShares$15.7 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$14.9 Million1.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $270M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...